Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4925258 | 0.88 | ESR2 (0.47) | ESR2NR1H2HRH3OPRM1OPRD1 | |
| SCHEMBL4913611 | 0.87 | OPRM1 (0.52) | ESR2HRH3OPRM1OPRD1OPRK1 | |
| SCHEMBL4913618 | 0.85 | HRH3 (0.52) | ESR2NR1H2HRH3OPRM1OPRD1 | |
| SCHEMBL3077276 | 0.84 | HRH3 (0.66) | ESR2NR1H2HRH3OPRM1OPRD1 | |
| SCHEMBL4926454 | 0.83 | ESR2 (0.50) | ESR2NR1H2HRH3OPRM1OPRD1 | |
| SCHEMBL4915892 | 0.82 | HRH3 (0.64) | ESR2NR1H2HRH3OPRM1OPRD1 | |
| SCHEMBL3082115 | 0.82 | HRH3 (0.52) | ESR2NR1H2HRH3OPRM1OPRD1 | |
| SCHEMBL3077662 | 0.81 | HRH3 (0.52) | ESR2NR1H2HRH3NPC1RAB9A | |
| SCHEMBL3691958 | 0.80 | OPRM1 (0.60) | NR1H2HRH3OPRM1OPRD1OPRK1 | |
| SCHEMBL3089265 | 0.80 | HRH3 (0.66) | ESR2NR1H2HRH3OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232590-A1 | 3-Cylcoalkylbenzazepines as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232590-A1 | 3-Cylcoalkylbenzazepines as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
| US-20070232590-A1 | 3-Cylcoalkylbenzazepines as Histamine H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232590-A1 | 3-Cylcoalkylbenzazepines as Histamine H3 Antagonists | HRH3, HRH4, HRH2 | ESR2 2743/4885NR1H2 1151/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.